Structural basis of p38 ± regulation by hematopoietic tyrosine phosphatase

Nature Chemical Biology

Volumn 7, Issue 12, 2011, Pages 916-924

  Francis, Dana M ^a   Rä, Bartosz ^b   Koveal, Dorothy ^c   Hummer, Gerhard ^b   Page, Rebecca ^c   Peti, Wolfgang ^a  

^a BROWN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMATOPOIETIC TYROSINE PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CATALYSIS; COMPLEX FORMATION; ENZYME ACTIVATION; ENZYME BINDING; ENZYME INACTIVATION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; KINASE INTERACTION MOTIF; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MOTIF; X RAY CRYSTALLOGRAPHY;

EID: 81355122666     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.707     Document Type: Article

References (48)

1. Raman, M., Chen, W. & Cobb, M.H. Differential regulation and properties of MAPKs. Oncogene 26, 3100-3112 (2007). (Pubitemid 46763006)
2. Kim, E.K. & Choi, E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 1802, 396-405 (2010).
3. Cobb, M.H. et al. Regulation of the MAP kinase cascade. Cell. Mol. Biol. Res. 40, 253-256 (1994). (Pubitemid 24349814)
4. Alonso, A. et al. Protein tyrosine phosphatases in the human genome. Cell 117, 699-711 (2004). (Pubitemid 38748887)
5. Wilson, K.P. et al. Crystal structure of p38 mitogen-activated protein kinase. J. Biol. Chem. 271, 27696-27700 (1996). (Pubitemid 26367339)
6. Kallunki, T. et al. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 8, 2996-3007 (1994).
7. Akella, R., Min, X., Wu, Q., Gardner, K.H. & Goldsmith, E.J. The third conformation of p38á MAP kinase observed in phosphorylated p38á and in solution. Structure 18, 1571-1578 (2010).
8. Chang, C.I., Xu, B.E., Akella, R., Cobb, M.H. & Goldsmith, E.J. Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol. Cell 9, 1241-1249 (2002). (Pubitemid 34722303)
9. Heo, Y.S. et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J. 23, 2185-2195 (2004).
10. Liu, S., Sun, J.P., Zhou, B. & Zhang, Z.Y. Structural basis of docking interactions between ERK2 and MAP kinase phosphatase
11. Proc. Natl. Acad. Sci. USA 103, 5326-5331 (2006).
12. Ma, W. et al. Phosphorylation of DCC by ERK2 is facilitated by direct docking of the receptor P1 domain to the kinase. Structure 18, 1502-1511 (2010).
13. Reményi, A., Good, M.C., Bhattacharyya, R.P. & Lim, W.A. The role of docking interactions in mediating signaling input, output, and discrimination in the yeast MAPK network. Mol. Cell 20, 951-962 (2005). (Pubitemid 41814883)
14. Zhou T., Sun L., Humphreys J., Goldsmith E.J Docking interactions induce exposure of activation loop in the MAP kinase ERK2. Structure 14 1011-1019 (2006). (Pubitemid 43831663)
15. Critton, D.A., Tortajada, A., Stetson, G., Peti, W. & Page, R. Structural basis of substrate recognition by hematopoietic tyrosine phosphatase. Biochemistry 47, 13336-13345 (2008).
16. Saxena, M., Williams, S., Brockdorff, J., Gilman, J. & Mustelin, T. Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTP). J. Biol. Chem. 274, 11693-11700 (1999).
17. Munoz, J.J., Tarrega, C., Blanco-Aparicio, C. & Pulido, R. Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38? is determined by a kinase specificity sequence and influenced by reducing agents. Biochem. J. 372, 193-201 (2003). (Pubitemid 36609621)
18. Tanoue, T., Adachi, M., Moriguchi, T. & Nishida, E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2, 110-116 (2000).
19. Zhang, J., Zhou, B., Zheng, C.F. & Zhang, Z.Y. A bipartite mechanism for ERK2 recognition by its cognate regulators and substrates. J. Biol. Chem. 278, 29901-29912 (2003). (Pubitemid 36962378)
20. Zanke, B. et al. Cloning and expression of an inducible lymphoid-specific, protein tyrosine phosphatase (HePTPase). Eur. J. Immunol. 22, 235-239 (1992).
21. Lombroso, P.J., Murdoch, G. & Lerner, M. Molecular characterization of a protein-tyrosine-phosphatase enriched in striatum. Proc. Natl. Acad. Sci. USA 88, 7242-7246 (1991). (Pubitemid 21915126)
22. Hendriks, W., Schepens, J., Brugman, C., Zeeuwen, P. & Wieringa, B. A novel receptor-type protein tyrosine phosphatase with a single catalytic domain is specifically expressed in mouse brain. Biochem. J. 305, 499-504 (1995).
23. Saxena, M., Williams, S., Tasken, K. & Mustelin, T. Crosstalk between cAMP-dependent kinase and MAP kinase through a protein tyrosine phosphatase. Nat. Cell Biol. 1, 305-311 (1999). (Pubitemid 129495782)
24. Bellon, S., Fitzgibbon, M.J., Fox, T., Hsiao, H.M. & Wilson, K.P. The structure of phosphorylated p38ä is monomeric and reveals a conserved activation-loop conformation. Structure 7, 1057-1065 (1999). (Pubitemid 29436503)
25. Diskin, R., Engelberg, D. & Livnah, O. A novel lipid binding site formed by the MAP kinase insert in p38á. J. Mol. Biol. 375, 70-79 (2008). (Pubitemid 350160682)
26. Masterson, L.R. et al. Dynamics connect substrate recognition to catalysis in protein kinase A. Nat. Chem. Biol. 6, 821-828 (2010).
27. Masterson, L.R., Mascioni, A., Traaseth, N.J., Taylor, S.S. & Veglia, G. Allosteric cooperativity in protein kinase A. Proc. Natl. Acad. Sci. USA 105, 506-511 (2008). (Pubitemid 351171738)
28. Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506 (2010).
29. Piserchio, A. et al. Solution NMR insights into docking interactions involving inactive ERK2. Biochemistry 50, 3660-3672 (2011).
30. Vogtherr, M. et al. NMR backbone assignment of the mitogen-activated protein (MAP) kinase p38. J. Bio Mol. NMR 32, 175 (2005). (Pubitemid 41102320)
31. Esposito, V. et al. NMR assignment of the cAMP-binding domain A of the PKA regulatory subunit. J. Bio Mol. NMR 36 (suppl. 1), 64 (2006).
32. Vajpai, N. et al. Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib. Bio Mol. NMR Assign. 2, 41-42 (2008).
33. Perry, J.J., Harris, R.M., Moiani, D., Olson, A.J. & Tainer, J.A. p38á MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses. J. Mol. Biol. 391, 1-11 (2009).
34. Hoffman, A.D., Urbatsch, I.L. & Vogel, P.D. Nucleotide binding to the human multidrug resistance protein 3, MRP3. Protein J. 29, 373-379 (2010).
35. Delannoy, S., Urbatsch, I.L., Tombline, G., Senior, A.E. & Vogel, P.D. Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy. Biochemistry 44, 14010-14019 (2005). (Pubitemid 41507481)
36. Fitzgerald, C.E. et al. Structural basis for p38á MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. 10, 764-769 (2003). (Pubitemid 37052417)
37. Vogtherr, M. et al. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew. Chem. Int. Edn Engl. 45, 993-997 (2006). (Pubitemid 43198494)
38. Kornev, A.P., Haste, N.M., Taylor, S.S. & Eyck, L.F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. USA 103, 17783-17788 (2006). (Pubitemid 44852237)
39. Mustelin, T., Tautz, L. & Page, R. Structure of the hematopoietic tyrosine phosphatase (HePTP) catalytic domain: structure of a KIM phosphatase with phosphate bound at the active site. J. Mol. Biol. 354, 150-163 (2005). (Pubitemid 41527220)
40. Jeeves, M., McClelland, D.M., Barr, A.J. & Overduin, M. Sequence-specific 1H, 13C and 15N backbone resonance assignments of the 34 kDa catalytic domain of human PTPN7. Bio Mol. NMR Assign. 2, 101-103 (2008).
41. Gong, H. & Freed, K.F. Electrostatic solvation energy for two oppositely charged ions in a solvated protein system: salt bridges can stabilize proteins. Biophys. J. 98, 470-477 (2010).
42. Róycki, B., Kim, Y.C. & Hummer, G. SAXS ensemble refinement of ESCRT-III CHMP3 conformational transitions. Structure 19, 109-116 (2011).
43. Balasu, M.C. et al. Interface analysis of the complex between ERK2 and PTP-SL. PLoS ONE 4, e5432 (2009).
44. Peti, W. & Page, R. Strategies to maximize heterologous protein expression in Escherichia coli with minimal cost. Protein Expr. Purif. 51, 1-10 (2007). (Pubitemid 44821862)
45. Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Bio Mol. NMR 6, 277-293 (1995).
46. Leonard, T.A., Rozycki, B., Saidi, L.F., Hummer, G. & Hurley, J.H. Crystal structure and allosteric activation of protein kinase C ?II. Cell 144, 55-66 (2011).
47. Yang, S., Blachowicz, L., Makowski, L. & Roux, B. Multidomain assembled states of Hck tyrosine kinase in solution. Proc. Natl. Acad. Sci. USA 107, 15757-15762 (2010).
48. Franke, D. & Svergun, D.I. DAMMIF, a program for rapid ab-initio shape determination in small-angle scattering. J. Appl. Crystallogr. 42, 342-346 (2009).